Posted by Michael Wonder on 02 Feb 2022
QSAM Biosciences receives rare paediatric disease designation from FDA for CycloSam in the treatment of osteosarcoma
2 February 2022 - QSAM Biosciences today announces that the United States FDA has granted rare paediatric disease designation to QSAM’s clinical stage drug candidate, CycloSam, for the treatment osteosarcoma, a devastating form of bone cancer that afflicts mostly children and young adults.
QSAM’s initial technology, CycloSam (Samarium-153 DOTMP), is a clinical stage bone targeting radiopharmaceutical developed by IsoTherapeutics, pioneers in the nuclear medicine space who also developed the FDA approved Quadramet (Samarium-153 EDTMP) radiopharmaceutical product, which is indicated for pain palliation.
